Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 March 2022 | Story André Damons
Dr Yolandi Swart
Dr Yolandi Swart, who took over from Prof Lynette van der Merwe as the new Director of the Undergraduate Medical Programme (MB ChB programme) in the School of Clinical Medicine within the Faculty of Health Sciences at the University of the Free State (UFS), says she is excited about the new opportunities that come with this position.

The new Director of the Undergraduate Medical Programme (MB ChB programme) in the School of Clinical Medicine within the Faculty of Health Sciences at the University of the Free State (UFS) has a passion for teaching and learning and brings a wealth of experience with her.

Dr Yolandi Swart, who took over from Prof Lynette van der Merwe on 1 March 2022, says she is excited about the new opportunities that this position brings. She was not actively job-hunting and came across the advertisement by accident but was thrilled when she was informed that she is the recommended candidate.

A deep love for the UFS

“I will be heading up an amazing team of people who drive the MB ChB programme, making sure that we walk with our students on their journey to become the next generation of health professionals who will contribute to the health and wellness of our population. Our functions include coordinating the undergraduate curriculum, providing student support, as well as logistic support to ensure the smooth running of the MB ChB programme,” says Dr Swart.

As an alumna of the university (she obtained both her MB ChB and postgraduate MMed in Community Health at the UFS), she has a deep love for the UFS, as it has played a huge role in developing her into the person she is today.

According to Dr Swart, she looks forward to getting to know the students and seeing them develop into the best they can be, as well as engaging with the academic staff as they guide and train the students. She brings a diverse background to the position, having practised as a doctor, specialised in Community Health, and worked in clinical research at various levels, including senior management. This has afforded her the opportunity to equip herself with skills that she hopes will provide support and direction to the Undergraduate Programme Management team in order to provide excellent service in all its functions.

Her vision

“I love teaching and learning – taking a concept and making it accessible to someone.  There are few things as satisfying as seeing that expression that says ‘Oh, now I get it!’

Kovsies has always had a reputation of producing excellent doctors.  “It is my vision to build on that reputation, integrating local and international best practices as they develop into our students’ training, with the aim of developing young professionals who are competent, resilient, and able to face the challenges that life will throw at them – so that they, in turn, can play their role to influence lives for the better.”

Prior to her appointment, she worked at FARMOVS as a clinical research physician for more than six years, the past year and a half as the company’s Medical Director. Says Dr Swart: “I love challenging myself with new things every so often. Past and present hobbies include surfing (which died an early death, as I was horrible at it), scuba diving (yes, with sharks as well), horse-riding, and self-defence.  Most recently, I got hooked on traditional archery – a very challenging skill to try and master.”

Dr Swart says she has learned throughout her personal life and professional career that life sometimes takes unexpected turns – but if one is open to the opportunities afforded by those unexpected turns, it often turns out so much better than the original plan could ever have been. “Difficulties and challenges will always come – but if one faces them with a positive attitude, they teach life skills that you would otherwise never have attained.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept